Short answer
Tyra Biosciences, Inc. (TYRA) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 8.01 (Other Events). SURF302 supports selective FGFR3 inhibition, with 60 mg QD identified as the potential registrational adjuvant dose.
Tyra Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- SURF302 supports selective FGFR3 inhibition, with 60 mg QD identified as the potential registrational adjuvant dose
- 60 mg cohort: 79% ORR and 64% best overall CR among 14 evaluable participants
- Favorable safety at 60 mg: no dose reductions, treatment-related discontinuations, Grade 4/5 TEAEs, or treatment-related Grade 3 AEs
- Exposure-response signal: 86% ORR above 2,500 ng·hr/mL versus 58% below the threshold
- TYRA plans 70 mg evaluation, health-authority discussions, and a potential registrational adjuvant study in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tyra Biosciences, Inc. 8-K filings
Get the next TYRA 8-K as it lands
Follow TYRA for push alerts, or ask the research agent what this filing means.